LifeTech Scientific (FRA:81X) EBIT: €23.2 Mil (TTM As of Dec. 2025)


FRA:81X LifeTech Scientific Corp FRA:81X
96 GF Score
Price €0.14
GF Value €0.21
! 4 Warning Signs
View Full Analysis

What is LifeTech Scientific EBIT?

LifeTech Scientific FRA:81X -0.71% 96 EBIT is €23.2 Mil as of Dec. 2025. GuruFocus rates FRA:81X with a GF Score™ of 96/100 and a GF Value™ of €0.21. The stock has 4 warning signs investors should review.

LifeTech Scientific's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €21.1 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €23.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. LifeTech Scientific's annualized ROC % for the quarter that ended in Dec. 2025 was 6.08%. LifeTech Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 32.84%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. LifeTech Scientific's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 4.43%.

LifeTech Scientific  (FRA:81X) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

LifeTech Scientific's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=38.458 * ( 1 - 36.76% )/( (367.552 + 431.845)/ 2 )
=24.3208392/399.6985
=6.08 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=644.018 - 108.029 - ( 168.437 - max(0, 119.932 - 310.713+168.437))
=367.552

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=607.765 - 73.375 - ( 139.451 - max(0, 179.381 - 281.926+139.451))
=431.845

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

LifeTech Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=42.286/( ( (120.167 + max(17.749, 0)) + (119.606 + max(-84.735, 0)) )/ 2 )
=42.286/( ( 137.916 + 119.606 )/ 2 )
=42.286/128.761
=32.84 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(24.778 + 59.595 + 52.939) - (108.029 + 0 + 11.534)
=17.749

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(19.618 + 53.945 + 20.627) - (73.375 + 0 + 105.55)
=-84.735

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

LifeTech Scientific's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=23.231/524.229
=4.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LifeTech Scientific EBIT Related Terms

LifeTech Scientific EBIT Historical Data

* Premium members only.

The historical data trend for LifeTech Scientific's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LifeTech Scientific EBIT Chart

LifeTech Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.62 51.28 22.64 26.35 23.24

LifeTech Scientific Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.63 20.03 5.83 2.09 21.14

FRA:81X vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, LifeTech Scientific's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LifeTech Scientific EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where LifeTech Scientific's EV-to-EBIT falls into.


FRA:81X
96GF Score
LifeTech Scientific Corp FRA:81X
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LifeTech Scientific EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €23.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €23.2 Mil mean?
LifeTech Scientific (FRA:81X) has a EBIT of €23.2 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on LifeTech Scientific.
Is LifeTech Scientific's EBIT too high?
LifeTech Scientific's current EBIT is €23.2 Mil. Overall, LifeTech Scientific has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does LifeTech Scientific's EBIT compare to ABT and SYK?
LifeTech Scientific's EBIT of €23.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on LifeTech Scientific. LifeTech Scientific's current EBIT is €23.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeTech Scientific stock overvalued right now?
LifeTech Scientific (FRA:81X) has a current EBIT of €23.2 Mil. The stock's GF Value™ is €0.21, compared to a current price of €0.14 — trading 33.3% below its estimated fair value. The current EBIT is €23.2 Mil. LifeTech Scientific's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For LifeTech Scientific (FRA:81X), the current EBIT is €23.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LifeTech Scientific (FRA:81X) Overvalued in 2026?

Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued. The current stock price of €0.14 is trading 33.3% below its estimated GF Value™ of €0.21.

Key valuation signals for FRA:81X:

  • EBIT: €23.2 Mil
  • GF Value™: €0.21 vs. price of €0.14 (33.3% below fair value)
  • GF Score™: 96/100 with 4 warning signs

No single metric tells the full story. See the FRA:81X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LifeTech Scientific Business Description

Other Exchanges 01302:Hong Kong
Address No. 22, Keji 12th Road South, 14th Floor, LifeTech Scientific Building, High-tech Industrial Park, Nanshan District, Shenzhen, CHN, 518063
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
96GF Score

Get the complete analysis for FRA:81X

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.21
GF Value